{
    "clinical_study": {
        "@rank": "30230", 
        "arm_group": [
            {
                "arm_group_label": "Paclitaxel plus raltitrexed", 
                "arm_group_type": "Experimental", 
                "description": "taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle"
            }, 
            {
                "arm_group_label": "taxol", 
                "arm_group_type": "Active Comparator", 
                "description": "taxol 135 mg/m2,  every three weeks for a cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate and compare safety and effectiveness of\n      Chemotherapy in Paclitaxel plus raltitrexed plug compare with taxol second-line treatment\n      for advanced gastric cancer"
        }, 
        "brief_title": "Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.18~75 years old 2.Pathological diagnosis of gastric cancer or gastroesophageal junction\n        adenocarcinoma 3.patient failed after The first line treatment of 5-Fu and platinum\n        ,patient relapse half year after using 5 - Fu and platinum as Postoperative adjuvant\n        chemotherapy 4.ECOG 0-1 5.At least one measurable objective tumor lesions\n        6.ANC\u22651.5*109/L\uff1bPLT\u226580*109/L\uff1bHB\u226590g/L\uff1bTBI\u22641.5(UNL); ALT\u3001AST\u22641.5ULN\uff1b Cr\u2264ULN\uff1bCcr\u226560ml/min\n        7.Expected survival period for 3 months or more 8. patients with voluntary participation,\n        and sign the informed consent\n\n        Exclusion Criteria:\n\n          1. Recurrence after transfer have received taxol or docetaxel as first-line\n             chemotherapy,If the adjuvant chemotherapy with paclitaxel,From the last chemotherapy\n             for 6 months or less\n\n          2. With uncontrollable large pleural or peritoneal effusion\n\n          3. In the near future has a history of myocardial infarction (3 months)\n\n          4. Malignant tumour of the past five years with other organizations to source, but the\n             full treatment of cervical carcinoma in situ and except skin basal cell carcinoma and\n             squamous cell carcinomas;\n\n          5. With brain metastasis\n\n          6. Severe uncontrolled medical disease or acute infection\n\n          7. Pregnancy or breast-feeding women\n\n          8. Has a long history of chronic diarrhea, or now complete intestinal obstruction\n             patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072317", 
            "org_study_id": "guoweijian-2013-raltitrexed"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paclitaxel plus raltitrexed", 
                "description": "taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle", 
                "intervention_name": "taxel plus raltitrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "taxol", 
                "description": "taxol 135 mg/m2,  every three weeks for a cycle", 
                "intervention_name": "taxol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Raltitrexed"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PFS", 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "email": "guoweijian1@hotmail.com", 
                "last_name": "GUO WEI JIAN, doctor", 
                "phone": "13816066360"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies", 
        "overall_contact": {
            "email": "guoweijian1@hotmail.com", 
            "last_name": "GUO WEI JIAN, doctor", 
            "phone": "13816066360"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "Since the date of random to disease progression or any cause of death\uff0cthe average time is 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072317"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Weijian Guo", 
            "investigator_title": "attending", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}